Optimize Financial Inc Invests $441,000 in Johnson & Johnson $JNJ

Optimize Financial Inc purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,377 shares of the company’s stock, valued at approximately $441,000.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC lifted its stake in Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the last quarter. Norges Bank bought a new stake in Johnson & Johnson in the second quarter worth approximately $4,877,174,000. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock valued at $4,568,313,000 after purchasing an additional 835,146 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $234.26 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $564.40 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35. The firm has a fifty day moving average price of $212.27 and a two-hundred day moving average price of $193.02. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $235.83.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The business had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. During the same quarter in the prior year, the business earned $2.04 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst upgrades and raised price targets are boosting investor sentiment — Bank of America raised its PT to $227 (from $221) and RBC raised its PT to $255 while keeping an Outperform rating, signaling confidence in JNJ’s outlook. BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why RBC Raises Price Target on Johnson & Johnson to $255
• Positive Sentiment: Clinical and commercial oncology updates are underpinning the longer‑term earnings thesis — recent ERLEADA and DARZALEX FASPRO data/updates are framed as material to JNJ’s oncology growth, and commentary expects oncology sales to roughly double over time. That bolsters the case for faster revenue/earnings ramp. ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story Johnson & Johnson’s Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?
• Positive Sentiment: Product and medtech momentum: JNJ MedTech announced Varipulse updates and a new ultrasound catheter, and ACUVUE launched a novel daily multifocal toric contact lens in the UK/Ireland — both moves expand near‑term commercial catalysts and diversify growth drivers outside pharma. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens
• Neutral Sentiment: Context piece: recent analysis highlights JNJ’s ~50% stock rally over the past nine months driven by improved earnings, product wins and legal progress — useful for sentiment context but not new company-specific catalyst. What’s Behind The 50% Surge In JNJ Stock?

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JNJ shares. Freedom Capital downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Stifel Nicolaus increased their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Argus upped their target price on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Finally, Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.